All News

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase I-III overactive bladder trials and phase IV BPH trials that are currently recruiting participants. This list is current as of April 19, 2012. For more information, view the complete database at http://ClinicalTrials.gov.

Urologists have just been hit with a solid left-right combination in a new round of the fight over self-referral. Within a month, they have had to counter two separate studies questioning their use of in-house pathology and radiology services.

Signs of the sea change to come in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) will be part of the 2012 AUA annual meeting. Next year should bring even more, as the National Institute of Diabetes and Digestive and Kidney Diseases and pharma research get readied for meeting debuts.

Attendees of the 2012 AUA annual meeting can anticipate learning about studies of sexual dysfunction that may have a significant impact on treatment paradigms.

Holding property in joint tenancy with rights of survivorship (JTWROS) generally provides no asset protection. In fact, JTWROS ownership exposes the property to the creditors of each of the joint tenants.

The program on advanced prostate cancer at the 2012 AUA annual meeting will include maturing data from clinical trials investigating targeted and vaccine therapies, as well as some preliminary information suggesting that folate may have a chemopreventive effect.

While cost remains a concern, incorporating robotics into urologic laparoscopy appears to improve the experience for patients and physicians alike.

Outcomes for men with prostate cancer are strongly related to risk category according to clinical stage, Gleason score, and serum PSA, and there is a continuous risk of death from the disease up to 15 years after diagnosis.

The newest urology products and services from Olympus, Teleflex, Inc., Medline Industries, Inc., and Wiley-Blackwell.

Observational data fail to support a role of 5-alpha-reductase inhibitors (5-ARIs) for secondary prevention of clinically significant prostate cancer in men with very low-risk disease.

There will always be a place for laboratory research in andrology, but the past year has been one of surgical advancements for those who diagnose and treat male infertility.

Low-dose computed tomography scans reduce radiation exposure while maintaining diagnostic quality in patients with stage I testicular germ cell tumors being managed with surveillance following orchiectomy.

Stone disease and minimally invasive treatment approaches are once again leading issues in the pediatric urology section of the 2012 AUA annual meeting.

This bonus "State of Urology" issue offers a sneak-peek at some of the outstanding research you'll learn more about at the AUA annual meeting in Atlanta.

The 2012 AUA annual meeting will reflect incremental progress occurring in the management of lower urinary tract symptoms (LUTS) secondary to BPH, as well as emerging information about the epidemiology and underlying biology of the disease process.

Dose titration of the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) to achieve therapeutic blood levels may be required for patients with metastatic renal cell carcinoma to derive optimal benefit from the drug as second-line therapy.

Several abstracts from this year's AUA annual meeting suggest that, just as bacteria alter their host environment to their benefit, treatments for infection and inflammation may counter by changing the host environment to pathogens' detriment.

Urologists agree that PSA screening will be the hot topic at the AUA annual meeting in Atlanta.

The FDA recently issued a complete response letter for Amgen Inc.'s supplemental Biologics License Application for the RANK ligand inhibitor denosumab (XGEVA) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases.

Uroplasty, Inc., has announced that Novitas Solutions (formerly Highmark Medicare Services) informed the Centers for Medicare & Medicaid Services that it has retired the non-coverage provisions concerning posterior tibial nerve stimulation (PTNS) from its local coverage determination effective for services incurred on or after April 9, 2012.

Urologists tied for fourth in salary in a recent survey of physician specialists.

The FDA recently approved new treatments for erectile dysfunction and renal angiomyolipomas, and a previously approved agent for overactive bladder has been launched.

Curious about how the U.S. Preventive Services Task Force's recently drafted recommendation against routine PSA screening for prostate cancer at any age would affect clinical practice, investigators at the University of Chicago Medical Center and UCLA studied the effect of a 2008 task force recommendation against screening in men aged 75 years or older and found there was none.

Excess body weight may be associated with an increased risk for cancer recurrence in men with clinically localized prostate cancer, according to a study presented at the American Association for Cancer Research annual meeting in Chicago.

A recently announced joint strategic partnership between the American College of Surgeons and the Centers for Disease Control and Prevention aims to combine expertise and resources to track, report, and prevent surgical-site infections (SSIs) and other adverse outcomes among surgical patients.

Bladder cancer patients receiving low doses of chemotherapy combined with radiotherapy were nearly 50% less likely to relapse with muscle-invasive disease compared with patients given radiotherapy alone, a recent study found.

Kidney cancer patients who underwent partial nephrectomy experienced better survival than patients who underwent radical nephrectomy, report researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.

High-intensity focused ultrasound offers significantly fewer side effects in treating prostate cancer than traditional treatments, according to a recent study.